Customer Education

Cell Line Engineering and the Cell Design Studio Webinar

Webinar Title: Cell Line Engineering and the Cell Design Studio

Date: Tuesday, March 27, 2018

Time: 11:00am EST

Duration: 60 minutes

 Private Webinar for Boehringer-Ingelheim


 What Does it Cover?

Gene editing has become a firmly established technology within the discovery sciences arena.  With the advent of CRISPR/Cas9 systems, the researcher's ability to find an active nuclease for nearly any region of any genome is now a reality. Even with better nucleases available, those who routinely use gene editing tools to manipulate cell lines encounter other significant challenges that pose a barrier to building the "correct" cell line model. As a well-established partner for custom cell line engineering, we at MilliporeSigma have encountered many of these challenges and have developed and/or implemented a number of methods to circumvent them. A summary of the various formats of CRISPR/Cas9 tools, and recommendations for when to use each will also be presented.

 What Will You Learn?

  • Newest strategies for clone screening and genotyping
  • Improved workflow for cell line characterization
  • Methods to overcome poor transfection efficiency
  • Strategies for recalcitrant cell lines
Speaker Bio
Mark Gerber, PhD
Principal R&D Scientist, Supervisor, Cell Design Studio
Mark obtained his Ph.D. in Biochemistry and Molecular Biology from Saint Louis University School of Medicine, where he used RNAi in Drosophila models to elucidate developmental and biochemical roles for RNA polymerase II-associated transcription factors. Following graduate school, he was a Postdoctoral Fellow at Washington University in St. Louis, where he investigated signaling pathways involved in the development of human meningioma. Mark joined MilliporeSigma in 2006, and has worked in the areas of biotherapeutic production, stem cell applications, and gene regulation. He currently supervises the Cell Design Studio team, which performs custom cell line engineering for research and pharma markets using ZFN and CRISPR technologies.